Trump announces trade deal with EU following months of negotiations
Paula Green, the Senior Vice President of Human Resources at Twist Bioscience Corp (NASDAQ:TWST), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Green sold 1,259 shares of common stock on February 3, 2025, at a price of $49.352 per share, totaling approximately $62,134. The stock, currently trading at $53.66, has shown strong momentum with a 43% return over the past year. According to InvestingPro analysis, the company’s stock price movements have been notably volatile.
This transaction was part of a mandatory "sell to cover" arrangement to fulfill tax withholding obligations related to the vesting of Restricted Stock Units. Such sales are mandated by Twist Bioscience’s equity incentive plans and are not discretionary trades by the executive. Following this transaction, Green retains ownership of 132,014 shares in the company. The company maintains a strong liquidity position with a current ratio of 4.96, indicating ample assets to meet obligations. For deeper insights into TWST’s financial health and more exclusive analysis, visit InvestingPro, where you’ll find additional ProTips and comprehensive research reports.
In other recent news, Twist Bioscience has been the subject of several analyst updates following their successful financial results for the first quarter of fiscal year 2025, which exceeded consensus predictions. Scotiabank (TSX:BNS) analyst Sung Ji Nam raised the company’s price target to $62 from $54, maintaining a Sector Outperform rating. The company’s full-year fiscal 2025 guidance was revised upward, with expectations for total revenue growth of 19-21% year-over-year.
Barclays (LON:BARC) analyst Luke Sergott also increased the price target on Twist Bioscience shares to $58, reiterating an Overweight rating. Sergott highlighted the potential for significant technological milestones and pilot commercial programs in DNA storage.
Baird reaffirmed its positive stance on Twist Bioscience, maintaining an Outperform rating and a $48.00 price target. The firm’s analyst noted strong demand for the company’s offerings, particularly in the academic and industry sectors.
TD Cowen maintained its Buy rating and a price target of $58.00, signaling confidence in the company’s revenue and gross margin outlook for fiscal year 2025 and beyond.
Lastly, following Twist Bioscience’s strong performance at the end of the fiscal year 2024, Scotiabank raised its price target to $54 from the previous target of $50. The firm maintained a Sector Outperform rating on the stock. These are some of the recent developments regarding Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.